1.CS-3000 Plus Cell Separator; A-35 Collection Chamber vs PLT-30TM Collection Chamber.
Oh Hun KWON ; Hyun Ok KIM ; Seun Moo LEE ; Hee Bong SHIN ; Chun Hyun NAHM
Korean Journal of Blood Transfusion 1996;7(1):49-55
BACKGROUND: Recently, it has been established that plateletpheresis needs more efficiency and shorter processing time. Fenwall laboratories developed a new collection chamber for CS-3000 Plus, PLT-30TM collection chamber, which can reduce the processing time with efficient collection. We evaluated the PLT-30TM collection chamber by comparing it with A-35 collection chamber that has been used as a standard collection chamber of CS-3000 Plus us. METHODS: Thirty platelet collection procedures were performed using the CS 3000 Plus with A-35 collection chamber and PLT-30TM collection chamber. The changes of the hematologic parameters between pre- and post-donation in donors and the total platelets yields and the contaminated WBCs in the plateletpheresis products were evaluated. In processing, the yield predictor calibration was adjusted to 1.00 and 1.13 in A-35 and PLT-30TM respectively. Yield predictors of pheresis were the same as 3.5x1011 in both and end point volumes were calculated from the CS-3000 Plus. Processing volume and processing times were compared between A-35 and PLT-30TM groups. RESULTS: With PLT-30TM collection chamber, 3.38+/-0.72x1011/L platelets were harvested, whereas 3.20+/- 0.73x1011/L were collected with A-35 collection chamber, which was not significantly different. But processing time with the PLT-30TM collection chamber was more reduced than that with the A-35 collection chamber by about 20 minutes (PLT-30TM : 88.6+/-8.4 min, A-35 : 106.7+/-11.7min). Collection efficiency of PLT-30TM chamber was 50.7+/-12.5% and that of A-35 chamber was 44.4 + 8.8%. The leukocyte contamination of the platelet concentrates were not statistically different(PLT-30TM: 0.0-3.6x106, A-35 : 0.1-4.1x106). CONCLUSIONS: PLT-30TM collection chamber has the advantages of shortening the donation time and decreasing the processing volume with better collection efficiency and flexibility of platelet concentrate volume.
Blood Component Removal
;
Blood Platelets
;
Calibration
;
Humans
;
Leukocytes
;
Plateletpheresis
;
Pliability
;
Tissue Donors
2.Complications in spinal cord injured patients.
Young Moo NA ; Chang Il PARK ; Saeil CHUN ; Jung Soon SHIN
Journal of the Korean Academy of Rehabilitation Medicine 1991;15(1):12-21
No abstract available.
Humans
;
Spinal Cord*
3.World Medical Association Guidelines on Promotional Mass Media Appearances by Physicians: Starting Campaigns for Ethics.
Moo Jin CHOO ; Dong Chun SHIN ; Cheong Hee KANG ; Hyun Young SHIN
Journal of Korean Medical Science 2015;30(12):1716-1717
No abstract available.
Ethics, Medical
;
Health Communication/ethics
;
Humans
;
Mass Media/*ethics
;
Physicians/*ethics
;
Republic of Korea
;
Social Support
;
Societies, Medical/ethics
4.The clinical analysis of traumatic occult pneumothorax in the emergency room
Chun Moo SHIN ; Seog Ki LEE ; Sang Hyun JOO ; Sun Pyo KIM
Journal of the Korean Society of Emergency Medicine 2024;35(6):377-383
Objective:
Traumatic occult pneumothorax is defined as a pneumothorax that cannot be identified with a simple chest X-ray and can be detected only by chest computed tomography (CT). The purpose of this study was to retrospectively recognize the difference between thoracostomy and conservative treatment of traumatic occult pneumothorax.
Methods:
Among the thoracic trauma inpatients who visited a single emergency room (ER) from January 2021 to May 2022, adult patients aged over 18 years, diagnosed with traumatic pneumothorax who survived their ER stay and with abnormalities were included as the final study subjects and their histories were compared.
Results:
Of the total of 269 thoracic trauma patients, 110 were diagnosed with traumatic pneumothorax, of which 30 were traumatic occult pneumothorax patients. Multiple logistic regression analyses performed in the traumatic occult pneumothorax patient group showed that as the pneumothorax size increased, the probability of finding an occult pneumothorax decreased (odds ratio [OR]=0.93; 95% confidence interval [CI], 0.89-0.98). In very severe cases of rib fractures (OR=0.65; 95% CI, 0.43-0.98), the probability of detecting occult pneumothorax was reduced. Among the patients with traumatic occult pneumothorax, 15 patients underwent thoracostomy. Cases of hemothorax (70%; P=0.05), surgery (26.67%; P<0.01), and higher injury severity scores (12.87±7.69; P=0.02) were more common in the thoracostomy group.
Conclusion
Usually traumatic occult pneumothorax is treated conservatively with regular follow-up, but thoracostomy is necessary when it is accompanied by hemothorax and for patients requiring surgery and having a higher injury severity score.
5.The clinical analysis of traumatic occult pneumothorax in the emergency room
Chun Moo SHIN ; Seog Ki LEE ; Sang Hyun JOO ; Sun Pyo KIM
Journal of the Korean Society of Emergency Medicine 2024;35(6):377-383
Objective:
Traumatic occult pneumothorax is defined as a pneumothorax that cannot be identified with a simple chest X-ray and can be detected only by chest computed tomography (CT). The purpose of this study was to retrospectively recognize the difference between thoracostomy and conservative treatment of traumatic occult pneumothorax.
Methods:
Among the thoracic trauma inpatients who visited a single emergency room (ER) from January 2021 to May 2022, adult patients aged over 18 years, diagnosed with traumatic pneumothorax who survived their ER stay and with abnormalities were included as the final study subjects and their histories were compared.
Results:
Of the total of 269 thoracic trauma patients, 110 were diagnosed with traumatic pneumothorax, of which 30 were traumatic occult pneumothorax patients. Multiple logistic regression analyses performed in the traumatic occult pneumothorax patient group showed that as the pneumothorax size increased, the probability of finding an occult pneumothorax decreased (odds ratio [OR]=0.93; 95% confidence interval [CI], 0.89-0.98). In very severe cases of rib fractures (OR=0.65; 95% CI, 0.43-0.98), the probability of detecting occult pneumothorax was reduced. Among the patients with traumatic occult pneumothorax, 15 patients underwent thoracostomy. Cases of hemothorax (70%; P=0.05), surgery (26.67%; P<0.01), and higher injury severity scores (12.87±7.69; P=0.02) were more common in the thoracostomy group.
Conclusion
Usually traumatic occult pneumothorax is treated conservatively with regular follow-up, but thoracostomy is necessary when it is accompanied by hemothorax and for patients requiring surgery and having a higher injury severity score.
6.The clinical analysis of traumatic occult pneumothorax in the emergency room
Chun Moo SHIN ; Seog Ki LEE ; Sang Hyun JOO ; Sun Pyo KIM
Journal of the Korean Society of Emergency Medicine 2024;35(6):377-383
Objective:
Traumatic occult pneumothorax is defined as a pneumothorax that cannot be identified with a simple chest X-ray and can be detected only by chest computed tomography (CT). The purpose of this study was to retrospectively recognize the difference between thoracostomy and conservative treatment of traumatic occult pneumothorax.
Methods:
Among the thoracic trauma inpatients who visited a single emergency room (ER) from January 2021 to May 2022, adult patients aged over 18 years, diagnosed with traumatic pneumothorax who survived their ER stay and with abnormalities were included as the final study subjects and their histories were compared.
Results:
Of the total of 269 thoracic trauma patients, 110 were diagnosed with traumatic pneumothorax, of which 30 were traumatic occult pneumothorax patients. Multiple logistic regression analyses performed in the traumatic occult pneumothorax patient group showed that as the pneumothorax size increased, the probability of finding an occult pneumothorax decreased (odds ratio [OR]=0.93; 95% confidence interval [CI], 0.89-0.98). In very severe cases of rib fractures (OR=0.65; 95% CI, 0.43-0.98), the probability of detecting occult pneumothorax was reduced. Among the patients with traumatic occult pneumothorax, 15 patients underwent thoracostomy. Cases of hemothorax (70%; P=0.05), surgery (26.67%; P<0.01), and higher injury severity scores (12.87±7.69; P=0.02) were more common in the thoracostomy group.
Conclusion
Usually traumatic occult pneumothorax is treated conservatively with regular follow-up, but thoracostomy is necessary when it is accompanied by hemothorax and for patients requiring surgery and having a higher injury severity score.
7.Clinical Study of Halo Nevi.
Jin Chun SUH ; Jung Sub YEUM ; Dong Ju SHIN ; Seon Kyo SEO ; Gun Yeon NA ; Moo Kyu SUH
Korean Journal of Dermatology 2001;39(6):648-653
BACKGROUND: There have been few clinical studies of halo nevi. OBJECTIVE: The purpose of this study was aimed at evaluating the clinical and histopathologic features of halo nevi and correlation between halo nevi and vitiligo. METHODS: The medical records of 40 patients with halo nevi and biopsy specimens of 30 patients with halo nevi were reviewed. RESULTS AND CONCLUSION: 1.The ratio of male to female patients was 1:1.5. 2.The mean age of the onset was 20.1 years (male : 11.5, female : 25.9). 3.Multiple halo nevi were present in 32.5%(male : 25%, female : 37.5%). 4.The areas in which the lesions developed were head and neck(39.1%), back(32.8%), anterior chest(12.5%), abdomen(10.9%), groin(3.1%), and lower extremity(1.6%) in descending order. 5.The mean duration of each color in central nevus was as follows: black(2.7 years), pink(3.5 years), gray(4.9 years) 6.The most common pathology of the central nevus was intradermal(80%). 7.The halo nevi associated with vitiligo were 21 cases(52.5%) out of 40 patients. Among them, the cases with non-segmental vitiligo were 13(61.9%), the cases with segmental vitiligo were 8(38.1%). 8.Out of the 21 cases with halo nevi associated with vitiligo, the cases with halo nevi prior to vitiligo were 4(19.1%), concurrent onset 12(57.1%) and the cases with halo nevi after vitiligo were 5(23.8%).
Biopsy
;
Female
;
Head
;
Humans
;
Male
;
Medical Records
;
Nevus
;
Nevus, Halo*
;
Pathology
;
Vitiligo
8.Production of tumor necrosis factor by intravesical administration of bacillus Calmette Guerin in patients with superficial bladder cancer.
Chun Il KIM ; Jeon Soo SHIN ; Hyung Il KIM ; Jin Moo LEE ; Se Jong KIM
Yonsei Medical Journal 1993;34(4):356-364
Although an immune response to bacillus Calmette Guerin (BCG) has often been associated with antitumor activity, the action mechanism(s) of intravesical BCG therapy for prophylaxis and treatment of superficial bladder cancer is not clearly understood. In an attempt to evaluate the roles of tumor necrosis factor (TNF)-alpha and lymphotoxin (LT) in the antitumor activity, TNF-alpha productivities by peripheral blood monocytes, serum levels of TNF-alpha, and LT productivities by peripheral blood lymphocytes were studied in superficial bladder cancer patients after six intravesical administrations of BCG. TNF-alpha productivities by peritoneal macrophages of guinea pigs were also studied after six intravesical administrations of BCG. The maximum TNF-alpha productivities by peripheral blood monocytes of superficial bladder cancer patients were seen after the fourth week of administration of BCG, and the serum TNF-alpha levels were also slightly increased after intravesical BCG administration in the superficial bladder cancer patients. LT productivities by peripheral blood lymphocytes of superficial bladder cancer patients were significantly enhanced and the maximum LT productivity was also seen after the third or fifth BCG administration. TNF-alpha productivities by peritoneal macrophages of guinea pigs were significantly enhanced and the maximum TNF-alpha productivity was seen after the second or third BCG administration. Our data might suggest that six consecutive intravesical BCG administrations could induce the increased productions of TNF-alpha and LT, which might play an important role in the antitumor activity in superficial bladder cancer.Although an immune response to bacillus Calmette Guerin (BCG) has often been associated with antitumor activity, the action mechanism(s) of intravesical BCG therapy for prophylaxis and treatment of superficial bladder cancer is not clearly understood. In an attempt to evaluate the roles of tumor necrosis factor (TNF)-alpha and lymphotoxin (LT) in the antitumor activity, TNF-alpha productivities by peripheral blood monocytes, serum levels of TNF-alpha, and LT productivities by peripheral blood lymphocytes were studied in superficial bladder cancer patients after six intravesical administrations of BCG. TNF-alpha productivities by peritoneal macrophages of guinea pigs were also studied after six intravesical administrations of BCG. The maximum TNF-alpha productivities by peripheral blood monocytes of superficial bladder cancer patients were seen after the fourth week of administration of BCG, and the serum TNF-alpha levels were also slightly increased after intravesical BCG administration in the superficial bladder cancer patients. LT productivities by peripheral blood lymphocytes of superficial bladder cancer patients were significantly enhanced and the maximum LT productivity was also seen after the third or fifth BCG administration. TNF-alpha productivities by peritoneal macrophages of guinea pigs were significantly enhanced and the maximum TNF-alpha productivity was seen after the second or third BCG administration. Our data might suggest that six consecutive intravesical BCG administrations could induce the increased productions of TNF-alpha and LT, which might play an important role in the antitumor activity in superficial bladder cancer.
Administration, Intravesical
;
Animal
;
Bladder Neoplasms/*metabolism/*therapy
;
Female
;
Guinea Pigs
;
Human
;
Mycobacterium bovis/*physiology
;
Prospective Studies
;
Support, Non-U.S. Gov't
;
Tumor Necrosis Factor/*biosynthesis
9.The Immunogenicity of a Single Dose of Hepatitis A Virus Vaccines (Havrix(R) and Epaxal(R)) in Korean Young Adults.
Jiseun LIM ; Yeong Jun SONG ; Woong Sub PARK ; Haesook SOHN ; Moo Sik LEE ; Dong Hoon SHIN ; Chun Bae KIM ; Hwasung KIM ; Gyung Jae OH ; Moran KI
Yonsei Medical Journal 2014;55(1):126-131
PURPOSE: Assessing the immunogenicity of a single dose of hepatitis A virus (HAV) vaccines is important because some people receive only a single dose. However, previous studies have shown variable results and have not examined the effects of demographic characteristics other than gender. This study was performed to examine the immunogenicity of a single dose of HAV vaccine according to the vaccine type and demographic characteristics in young adults. MATERIALS AND METHODS: Seronegative medical school students were randomly allocated to receive either Havrix or Epaxal. RESULTS: After approximately 11 months, the seroconversion rate in 451 participants was 80.7%. In men, the Havrix group showed a significantly higher seroconversion rate (81.9%) than the Epaxal group (69.2%), whereas both vaccine groups showed similarly high immunogenicity in women (Havrix: 90.1%, Epaxal: 92.9%; P for interaction=0.062). According to the results of a multivariate analysis, Epaxal showed significantly lower immunogenicity than Havrix only in men. Age, obesity, drinking, smoking, and follow-up time did not significantly affect seroconversion in either gender. CONCLUSION: The seroconversion rate of single-dose HAV vaccines was low in men, particularly in those who received Epaxal. Our results suggest that gender effects should be considered when comparing the immunogenicity of different HAV vaccines.
Adolescent
;
Adult
;
Female
;
Hepatitis A/*immunology/*prevention & control
;
Hepatitis A Vaccines
;
Hepatitis A Virus, Human/*immunology/*pathogenicity
;
Humans
;
Male
;
Young Adult
10.Effect of Central Losartan on DOCA-Salt Hypertension Rats.
Seung Jin LEE ; Chang Gyu PARK ; Jae Suk PARK ; Eung Ju KIM ; Sung Hee SHIN ; Dong Gyu JIN ; Jung Chun AHN ; Hong Seog SEO ; Dong Joo OH ; Young Moo RO
Korean Circulation Journal 2004;34(1):84-91
BACKGROUND: The purpose of this study was to investigate whether brain AT1 receptor stimulation contributes as a hypertensive mechanism to deoxycorticosterone acetate (DOCA)-salt hypertension. METHODS: 1) Acute injection:Losartan (1 mg/4 uL) or artificial cerebrospinal fluid (aCSF) was injected into the lateral cerebral ventricle (icv) of conscious control uninephrectomized Wistar rats or rats with DOCA-salt at 2 or 4 weeks, and mean arterial pressure (MAP) and heart rates (HR) were recorded. 2) Chronic injection:Using osmotic minipump, losartan (1 mg/kg/d) or aCSF was injected to a sham group or three DOCA-salt rat groups [icv-aCSF, icv-losartan, sc-losartan (subcutaneous) groups] for 4 weeks, after which the MAP and HR were recorded in addition to the weights of the left (LV) and right ventricles (RV) and kidneys. RESULTS: 1) Acute injection: In rats treated with DOCA-salt, resting MAP significantly increased compared to the control group [144+/-6 mmHg (2 weeks), 170+/-5 mmHg (4 weeks) vs 115-120 mmHg (controls)]. MAP decreased significantly (2 weeks, 4 weeks) at 4, 8, 24 hours after icv injection of losartan to the level of the control group. 2) Chronic injection: The general trend showed that MAP decreased more in the icv-losartan group than in the icv-aCSF group (127+/-15.2 mmHg vs 141.1+/-5.5 mmHg, p=0.0578). In all DOCA-salt groups, no differences in RV weight were found. In the icv-aCSF and sclosartan groups, the kidney weight increased compared to the control group, but there was no difference in LV and kidney weight between the icv-losartan group and the control group. CONCLUSION: Normalization of MAP after acute or chronic icv administration of the AT1 receptor antagonist suggests that the stimulation of the brain AT1 receptor plays a significant role in the development and maintenance of hypertension in the DOCA-salt hypertensive rat model. Losartan icv injection appeared to have a protective effect on the heart and kidney.
Angiotensin II
;
Animals
;
Arterial Pressure
;
Brain
;
Cerebral Ventricles
;
Cerebrospinal Fluid
;
Desoxycorticosterone
;
Heart
;
Heart Rate
;
Heart Ventricles
;
Hypertension*
;
Kidney
;
Losartan*
;
Models, Animal
;
Rats*
;
Rats, Wistar
;
Receptor, Angiotensin, Type 1
;
Weights and Measures